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New medical tests used by companies to lower health risks also can be 
used to Increase profits at workers' expense. Michael Baram, L.L.B., 
heads a BUSM team working to provide a foundation upon which officials 
can base guidelines governing the use of these tests. See story on page 3. 
An infant diet ricfi in sugar and an amino acid called tryptophan someday may provide relief for 
parents whose fussy newborn infants won't go to sleep. (Photo by Bradford F. Herzog) 
BUSM study shows babies sleep better 
when diets contain more sugar, protein 
For frustrated parents wfiose fussy 
newborn infants won't go to sleep, 
an infant diet rich in sugar and tryp-
tophan, an amino acid that is a part 
of protein, someday may provide 
relief, a Boston University School of 
Medicine researcher and his col-
league have found. 
Although this finding does not pro-
vide an immediate solution for par-
ents or physicians trying to cope with 
fussy infants, it does shed added 
light on the link between diet and the 
function of the brain and central ner-
vous system in humans, and 
increases the likelihood that one day 
a special infant formula may be 
available to promote sleep in new-
borns. The research also has impor-
tant implications for premature and 
other high-risk infants who must be 
fed by tubes or intravenously, for 
those infants who fail to thrive due to 
excess irritability, and for breastfed 
infants whose mothers are malnour-
ished. 
In the study, Steven H. Zeisel, 
M.D., Ph.D., an assistant professor 
of pathology and pediatrics at BUSM, 
continued on page 2 
Researchers study 
impotence; restore 
potency in some 
injured patients 
Impotence has long been considered 
a condition brought on primarily by 
psychological factors. Investigators at 
Boston University School of Medi-
cine, however, have found that in 
many cases the cause of the condi-
tion may be entirely physiological— 
and they are actively working to find 
better ways to overcome the underly-
ing problems. 
In the vast majority of cases of 
physiological origin, the BUSM 
researchers suggest, the cause is an 
atherosclerotic buildup in the arteries 
of the penis—the same problem that 
in coronary arteries can lead to a 
heart attack. The researchers 
already have devices that can be 
implanted in patients that allow the 
recipients to produce erections by 
artificial means. Now, though, they 
are seeking to develop an actual 
cure for that form of impotence that 
stems from atherosclerotic buildups. 
It is a prospect that, if fulfilled, 
could have an impact on the lives of 
literally millions of people. It is esti-
mated that 14 million men are 
affected by impotence, and the 
researchers believe that atheroscle-
rosis may be the cause in as many 
as half of these cases. 
Meanwhile, the researchers 
already have found a way to cure a 
continued on page 5 
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Diet-sleep study... 
continued from page 1 
and Michael W. Yogman, M.D., 
M.Sc, an assistant professor of pedi-
atrics at Harvard Medical School and 
associate chief of the Division of 
Child Development at Children's 
Hospital Medical Center in Boston, 
found that infants who prior to bed-
time are fed formulas with higher 
contents of both sugar and trypto-
phan—one of the 20 amino acids 
that make up protein and are neces-
sary in the diet for normal human 
growth and development—fell asleep 
14 minutes faster than those who 
received a regular commercial infant 
formula. 
"Our work is another step along 
the path that shows that the compo-
sition of the feeding infants receive 
before sleep determines how long it 
takes them to go to sleep and how 
long they stay in different levels of 
sleep," Zeisel said of the study, 
which recently received a great deal 
of national media attention after it 
appeared in the New England Jour-
nal of Medicine. The study was sup-
ported by the Robert Wood Johnson 
Foundation, the Carnegie Corpora-
tion, the National Institute of Mental 
Health, the National Institutes of 
Health and the National Foundation 
of the March of Dimes. Zeisel, a 
pediatrician and neurochemist, is a 
fellow of the John A. Hartford Foun-
dation. 
In the study, the researchers com-
pared over a six-month period the 
sleep patterns of 20 healthy two- and 
three-day-old infants born at two 
Boston hospitals. The infants were 
fed by their parents during their eve-
ning feedings either a standard com-
mercial infant formula, Similac, or 
two experimental formulas containing 
mixtures of glucose (sugar) and 
amino acids. The infants then were 
taken to dimly lit, quiet observation 
rooms, where they were changed 
and then placed in isolettes. There 
the infants' sleep patterns were 
recorded at one-minute intervals for 
the next three hours. Both observers 
and the parents were kept "blind" to 
the type of formula the infants 
received. 
One of the experimental formulas 
contained tryptophan, an amino acid 
known to trigger in the brain the 
secretion of a chemical neurotrans-
mitter, serotonin, and thus bring 
about sleep. (Tryptophan had been 
found in studies by other investiga-
tors to bring about sleep in adult 
humans and in laboratory animals.) 
This formula also contained a rela-
tively high (10 percent) sugar solu-
tion. 
The other formula contained half 
the amount of sugar as the other 
experimental formula (added only to 
improve the taste) and valine, an 
amino acid or carrier-protein that 
competes with tryptophan for entry 
into the brain. The amounts of amino 
acids in both experimental formulas 
were equivalent to the amounts of 
those substances in human breast 
milk and in commercial infant formu-
las. 
The infants ted the tryptophan for-
mula before bedtime entered active 
sleep—the first sleep stage tor new-
borns—14 minutes sooner, and quiet 
sleep—the level in which adults enter 
into sleep—20 minutes sooner than 
those fed Similac, which contains all 
the essential amino acids but falls in 
the middle of the experimental for-
mulas in terms of sugar. Those ted 
Steven H. Zeisel, M.D., Ph.D., compiles data 
in his lab. (Photo by Bradford F. Herzog) 
the valine formula entered active 
sleep about 16 minutes later, and 
quiet sleep 39 minutes later, than 
those ted Similac. 
Although the amount of time the 
infants spent in sleeping and waking 
states was not significantly different, 
there were differences. The infants 
ted tryptophan spent an average of 8 
minutes more in active sleep, 14 
minutes more in total sleep, and 
nearly 8 minutes less in a wakeful, 
alert state than those ted Similac. 
Those infants ted the valine formula 
spent an average of nearly 22 min-
utes less in active sleep, 36 minutes 
less in total sleep, and nearly 32 
minutes more in the wakeful state 
than those receiving Similac. 
"Pure sugar causes you to secrete 
the hormone insulin. Insulin causes 
muscle to take up valine, leucine and 
isoleucine (which are other amino 
acids) and then degrade these amino 
acids," Zeisel explained. "So the hor-
mone insulin removes the competi-
tion, and thus increases tryptophan's 
chance to reach the brain." 
While it could be harmless tor a 
nursing mother to eat a candy bar or 
some type of carbohydrate before 
the infant's bedtime feeding, Zeisel 
cautions that the study does not 
prove that this is the answer for par-
ents of fussy babies. For instance, 
he said, most American mothers get 
enough tryptophan in their normal 
diets to ensure an adequate supply 
in breast milk, and most commercial 
formulas contain an equal amount. 
However, studies in Central and 
South America have found deticien-
cies in amino acid content of breast-
feeding mothers in Guatemala 
(where the diet is corn-based) and 
Equador. 
Although tryptophan can be pur-
chased in health food stores, Zeisel 
warns parents not to feed it to 
infants, since little Is known about 
the long-term effects of imbalanced 
amino-acid diets on infants' growth 
and development. 
"We will now do more studies 
using artificial sweetners so we can 
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Study examines corporate medical tests: 
Lowering health risks or upping profits? 
separate the ettect ot sugar trom that 
ot the tryptophan," Zeisel said. "We 
also want to examine the effects of 
the infant's age on the study, and we 
want to study the effects ot new 
foods as they are added to the 
infants' diets." 
Another ot Zeisel and Yogman's 
next research ventures will be to 
evaluate how infant behavior is 
affected by choline, a vitamin-like 
nutrient found in the outer mem-
branes of all living human cells. Cho-
line, which is found in milk, influ-
ences the brain's synthesis of the 
neurotransmitter acetylcholine, which 
is important in memory function. 
"Other investigators have shown 
that the administering of choline-con-
taining compounds can be used to 
treat diseases of the brain involving 
deficiencies in choline transmission— 
such disorders as tadive dyskinesia, 
a side ettect of anti-psychotic drugs," 
Zeisel said. 
It already is known that newborns 
have high concentrations of choline 
in their bodies, tour to six times that 
of adults, perhaps as a natural pro-
tective device. "We have shown that 
both human babies and rats have 
blood levels that are as high as that 
of adults treated with choline ever 
get, and that their brain composition 
of choline is very high," Zeisel said. 
Using animal models, the re-
searchers also will study the absorp-
tion of choline from the gut, how it 
gets into the bloodstream, and the 
relation of the body's metabolism ot 
choline to its absorption of cancer-
causing chemicals. Their preliminary 
studies have shown that choline is 
not metabolized as quickly in the 
liver of baby rats as it is in adult rats. 
— Marjorie H. Dwyer 
Suggested Further Readings 
1. Yogman, M.W. and Zeisel, S.H.: Diet and 
sleep patterns in newborn infants. NEJM 
309: 1147-1149, 1983. 
2. Fernstrom, J.D. and Wurtman, R.J.: Brain 
serotonin content: Physiological regulation 
by plasma neutral amino acids. Science 
778: 414-416, 1972. 
—A woman will be hired to work at a 
ohemioal plant only if she provides 
medioal proof of her inability to 
become pregnant, or agrees to take 
periodic tests to prove she isn't 
pregnant, because the work environ-
ment may be harmful to a fetus. 
—An executive finds his climb up 
the corporate ladder halted because 
a routine company medioal examina-
tion reveals he may be susceptible 
to heart attack or ulcers—problems 
for which the company may have to 
pay in medioal benefits and lost pro-
ductivity. 
Scenarios such as these can occur 
at any time in today's society with 
our increasing ability to detect possi-
ble medical conditions before they 
become manifest as illness or dis-
ease. 
Progress in the fields ot biological 
monitoring and genetic screening 
has come very quickly—so quickly, 
in tact, that there is little law or 
expert consensus to govern how, 
when and to what extent these diag-
nostic techniques may be used in the 
workplace. 
In what is believed to be the first 
study ot its kind, a research team 
headed by Michael Baram, L.L.B., of 
Boston University School of Medi-
cine, is conducting a comprehensive 
analysis of the legal, ethical and pol-
icy issues surrounding the use of 
biological monitoring, medical surveil-
lance and genetic screening in the 
workplace. 
Baram, a professor of health law 
at BUSM's School ot Public Health, 
said he hopes this study will provide 
a foundation upon which regulatory 
otticials, medical authorities and cor-
porate managers can base guide-
lines governing the use of this 
increasing sophistication and applica-
tion of such technology. 
Biological monitoring is used with 
increasing frequency to periodically 
check employees—through such 
methods as blood, breath or urine 
tests—tor levels ot toxic chemicals in 
the body. If unsafe levels ot a sub-
stance are found, or it biological 
responses indicate increased risk, 
that person can be removed trom the 
work area where the chemical is 
used until the risks are reduced. 
With genetic screening, the analy-
sis of a person's genetic traits, physi-
cians are able to tell before a person 
is hired if he or she is susceptible to 
certain diseases or problems trom 
anticipated workplace exposures to a 
certain chemical or agent. Conse-
quently, the job applicant can be 
excluded trom certain jobs to prevent 
later health problems and their costs. 
"These diagnostic techniques have 
proven very useful for preventing 
health risks to workers and job appli-
cants. On the other hand, they have 
the potential to be used as tools pri-
marily for corporate cost control," 
said Baram, whose work is being 
funded by the National Science 
Foundation and the National Endow-
ment for the Humanities. 
Workers and trade unions worry 
that with the use of these tech-
niques, otherwise qualified employ-
ees may find themselves frozen out 
ot or terminated trom certain jobs 
because ot potential health prob-
lems. Instead of being responsible 
for keeping the workplace safe for all 
workers, companies could use only 
those workers most resistant to the 
toxic substances and health prob-
lems found In certain work areas, 
Baram explained. 
Corporate leaders also have reser-
vations about the use of such test-
ing. With these techniques becoming 
both more available and more 
sophisticated, workers could blame 
employers for health problems the 
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Michael Baram, L.L.B., hopes this study will 
provide a foundation upon which authorities 
can base guidelines governing biological 
monitoring and screening in the workplace. 
(Photo by Bradford F. Herzog) 
workers suffer, on the grounds that 
the companies should have used 
available medical testing. Workers 
also will have access to test results, 
and this would help them prove the 
cause of their injuries or diseases in 
tort litigation and workers' compensa-
tion claims. 
Since there has been practically 
no research done to date on these 
issues, the BUSM researchers' first 
step when they began the project in 
late 1980 was to determine to what 
extent these diagnostic techinques 
already were being used in industry. 
"We talked to people in various 
trade associations and companies in 
an attempt to find out their interest in 
these types of techniques and the 
extent to which they seem to be 
applied," said Baram. 
"Once we gained information on 
current usage ot these techniques, 
the next step was to look at how 
these methods are actually designed 
as systems tor use in industry," said 
Baram. 
"We're interested in learning the 
purposes behind use ot these sys-
tems," said Baram. "Are they 
designed to reduce workers' com-
pensation claims? Are they designed 
to reduce the workers' use ot the 
medical-benefits program?" 
Some companies are using these 
techniques defensively, to control 
costs or to prevail against claimants 
and litigants, said Baram. For exam-
ple, people with diabetes can be 
screened out ot jobs, not because 
they are unproductive or unqualified, 
but because statistically they will use 
the company's medical-benefit pro-
grams more frequently. 
In another aspect of the vast inter-
disciplinary study, the researchers 
are evaluating the medical issues 
involved in these techniques. 
Study co-investigator David P. 
Ozonott, M.D., chief ot the Environ-
mental Health Section at the School 
ot Public Health, is examining the 
accuracy and safety ot these tests. It 
a test is not proven sate, tor exam-
ple, employees shouldn't have to be 
subjected to it. Also, it a test isn't 
accurate, workers can find them-
selves tired trom a job because ot a 
mistake or misjudgment. 
Another aspect being studied by 
Ozonott, a BUSM associate profes-
sor ot socio-medical sciences and 
community medicine, is the "reason-
ableness" ot the tests. Many ot the 
tests—such as urine, blood and 
breath tests—are routine and rela-
tively noninvasive. However, some 
are very invasive—such as tests ot 
lung fluid, spinal fluid and sperm. 
Though one would assume that 
workers should not feel obligated to 
take such tests, fears for job security 
may force them to do so. 
The study, which is now being 
completed and scheduled for publi-
cation this tall, also analyzes legal 
issues, the government's role and 
the ethical aspects ot using such 
monitoring and screening in the 
workplace, said Baram, who also is 
an adjunct professor of law at Boston 
University School of Law. 
"Between the National Institute tor 
Occupational Safety and Health 
(NIOSH) and the Occupational 
Safety and Health Administration 
(OSHA) there is considerable gov-
ernmental interest in these tech-
niques, and also considerable sensi-
tivity as to what the potential 
problems are," said Ozonott. 
The ethical problems are becom-
ing more clear as the techniques are 
becoming more sophisticated. 
"Consider an employer advertising 
for job applicants tor a position 
involving such high-physical exertion 
as loading trucks," said Baram. "Fifty 
people apply; all go through job 
screening." 
In this scenario, Baram explained, 
all the applicants are physically quali-
fied tor the job. However, through 
medical tests, three people are found 
to have had prior back injuries and 
several others are identified as alco-
holics or users ot narcotics. 
"It's very tempting tor companies 
with the ability to use occupational 
medicine for cost containment to 
reject those applicants who pose 
higher risk of cost to the company," 
said Baram. "Employers can do this. 
However, since it creates new forms 
ot discrimination in hiring, these are 
legal issues that have not been fully 
addressed by our equal employment 
opportunity laws." 
Baram said there are many other 
medical, legal and ethical issues 
involved in the use of biological mon-
itoring and genetic screening. 
"We have all the ingredients for a 
series of legal and social problems, 
some ot which already have become 
real controversies," said Baram. "We 
now have to start fashioning some 
safeguards in the system to prevent 
misuse ot these techniques and to 
facilitate their use tor proper pur-
poses." 
— Paul D. Vaskas 
Suggested Further Readings 
1. Baram, M. et al (eds.): Biological Monitoring 
and Genetic Screening in the industrial 
Workplace. Conference Proceedings, Amer-
ican Society of Law and Medicine, Boston, 
Mass., 1983. 
2. Berlin, A. et ai (eds.): Assessment of Toxic 
Agents at the Workplace. Nijhoff Publish-
ers, the Hague, the Netherlands, 1984. 
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Impotence studies... 
continued from page 1 
type ot impotence that results trom 
damage to the artery that supplies 
blood to the penis. 
"The origins ot the new technique 
date back several years," said Irwin 
Goldstein, M.D., an assistant profes-
sor ot urology at BUSM, co-director 
ot University Hospital's New England 
Male Reproductive Center and direc-
tor ot the Male Reproductive Center 
at Boston City Hospital. 
"We see approximately 500 men a 
year who are suffering trom impo-
tence," said Goldstein, "and in 
roughly 50 to 65 percent ot the 
cases, the impotence is partly, or 
entirely, physiological in origin." 
Since many ot these patients are 
in their 50s and 60s, atherosclerotic 
buildup has been regarded as a 
likely explanation for their condition. 
That is the age, after all, when athero-
sclerosis often becomes a serious 
problem in the coronary arteries. For 
some ot the patients Goldstein and 
his colleagues saw during the late 
1970s and early 1980s, though, ath-
erosclerotic buildup seemed an 
unlikely source tor the problem. 
"These were men who were in 
their 20s and 30s," said Goldstein. 
"Most people assume that when men 
this age are impotent. It is a psycho-
logically generated problem, and in 
fact most of the patients had been 
initially referred to psychiatrists and 
psychologists. But in many cases, 
we felt that their problem was more 
likely to be physical in nature." 
By a happy coincidence, Goldstein 
was involved in a clinical research 
project that would eventually explain 
the impotence in these men and 
would allow many of them to be 
cured. 
The investigator was working with 
a BUSM colleague, Ronald W. Mor-
tara, M.D., an assistant professor ot 
neurosurgery who has broad experi-
ence in microsurgical bypass tech-
niques. Drawing on findings by a 
Irwin Goldstein, M.D., estimates tine success 
rate of the penile revascularization procedure 
to be 75 to 85 percent. (Photo by Lewis Glass, 
Educational Media, BUSM) 
noted Czech vascular surgeon that a 
form ot artery transplantation helps 
some patients with physiologically 
based impotence, the investigators 
decided to attempt the technique in 
some ot the patients who were com-
ing to University Hospital or Boston 
City Hospital. 
The operation, said Goldstein, 
involves repositioning an artery that 
supplies blood to a muscle in the 
lower abdomen. "What we do," he 
explained, "is to anastomose this 
artery into an artery that supplies 
blood to the penis." 
Robert J. Krane, M.D., professor 
and chairman ot the Department ot 
Urology, suggested inserting the 
donor artery directly into the end ot 
the artery ot the penis rather than 
into the side, as had been previously 
performed. This ditterence may have 
allowed tor an easier, more reliable 
microsurgical anastomosis, according 
to Goldstein. 
In 1982, Goldstein and Mortara 
used the new technique to treat an 
initial group ot 15 patients. The oper-
ation had little ettect on the older 
members ot the group, but it did 
have a dramatic effect on the 
younger men. 
Knowing that atherosclerosis prob-
ably was not the reason tor the loss 
ot blood flow that had affected the 
younger men, Goldstein began look-
ing tor alternative explanations. Inter-
views with them, and with other 
young men suffering trom impotence, 
disclosed that a number had sus-
tained severe blows to an area at the 
base ot the penis—a place where 
the main artery supplying the organ 
lies in close proximity to the pelvic 
bony structures. 
"We had some patients who were 
bicycle riders," said Goldstein. "They 
would tell us that they hit a pothole 
or something, and came down onto 
the bicycle frame. One ot our 
patients was a paratrooper who 
landed on his perineum, and one 
was a construction worker who 
landed on a 4-by-4. We've had 
patients who have become injured by 
being kicked." 
So tar, said Goldstein, he and his 
associates have treated about 35 
patients affected by such injuries. He 
estimates the operation's success 
rate at about 75 to 85 percent. 
There often is more to successful 
treatment, however, than simply res-
toring a patient's physical capacity to 
get erections, said Goldstein. 
"Younger patients are often pro-
A scanning electron micrograph of erectile 
tissue demonstrates the central artery of the 
penis and the erectile tissue spaces in a 
monkey. This artery receives additional blood 
inflow as a result of the revascularization 
procedure. (Photo in cooperation with Alan 
Nelson, Ph.D., director of the Whitaker 
Laboratory of Microscopy, MIT.) 
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toundly attected by impotence," he 
said. "They lose their jobs, drop out 
ot school and get into petty thievery, 
drugs or alcohol. 
"We discovered early on that these 
patients otten need a lot of counsel-
ing to help them readjust. So we 
work very closely with our colleagues 
in psychology. Alma D. Smith, Ph.D, 
an associate professor ot psychiatry 
(psychology) has tollowed all ot 
these patients. We've seen some 
remarkable changes take place— 
patients who tind new jobs, return to 
school, term new relationships and 
basically rejoin society." 
Meanwhile, Goldstein and a col-
league are planning a new research 
venture aimed at determining 
whether normal penile tunctions can 
be restored in men whose impotence 
stems trom atherosclerotic buildups. 
At present, if a patient's impotence 
stems from atherosclerosis or similar 
causes, Goldstein and his associates 
otten implant devices that allow 
patients to produce erections artifi-
cially. 
The new approach, according to 
the urologist, is to apply a technique 
already used to treat atherosclerotic 
buildups in coronary arteries. The 
technique is called transluminal 
angioplasty. It involves threading a 
specially designed catheter through 
the artery until it reaches the region 
where the vessel is narrowed. Then, 
an elongated balloon at the end of 
the catheter is carefully inflated. It 
presses against the buildups and 
restores the blood vessel to roughly 
its original width. 
Working with Goldstein on the 
project is David P. Faxon, M.D., an 
associate professor ot medicine at 
BUSM and director ot the Cardiac 
Catheterization Laboratory at Univer-
sity Hospital. Goldstein said that he 
and Faxon will simultaneously work 
with lab animals. 
"The idea would be to perform 
transluminal angioplasty microsurgi-
cal bypass procedures and vasodila-
tor therapies in several laboratory 
animals," he said. "We can then 
decide what procedures are able to 
etfectively restore penile erections 
given certain locations of atheroscler-
otic buildup." 
Goldstein noted that while angio-
plasty has proven itself in heart 
patients, patients whose atheroscle-
rosis has led to impotence may be 
more ditticult to treat by that method. 
"When atherosclerosis occurs in 
the penile arteries, you also may get 
changes in the structure ot the erec-
tile tissue," he explained. "The tissue 
becomes scarred, there is less elas-
tic tissue, and there have been 
changes in the erectile smooth mus-
cle. There also may be changes in 
the venous drainage of the penis. So 
in trying to cure impotence caused 
by atherosclerosis, we may be deal-
ing with a more complex problem 
than simply restoration ot blood 
flow." 
In light of this potential problem, 
Goldstein and Inigo Saenz de 
Tejada, a urology research fellow, 
have been working closely with Sami 
Harawi, M.D., an associate professor 
ot pathology, on a related project. 
"We will examine erectile tissues that 
have been removed trom patients in 
the normal course of penile-implant 
operations," said Goldstein. "We 
hope that by correlating vascular risk 
factors to pathological findings we 
will be able to recognize what risk 
factors result in excessive damage to 
the erectile tissues. Then we'll have 
a way ot knowing who is a good can-
didate tor the procedure and who is 
not." 
Others involved in the studies 
include Mike B. Siroky, M.D., an 
associate professor ot urology; Rich-
ard K. Babayan, M.D., an assistant 
professor ot urology; and Terry Pay-
ton, R.N. Funding is provided by the 
National Institutes of Health. 
— Richard P. Anthony 
Suggested Further Readings 
1. Krane, R.J. et al (eds): Male Sexual Dys-
function. Little Brown and Co., Boston, 
Mass., 1983. 
2. Michal, v., et al: Femoral pudendal bypass 
in the treatment of sexual impotence. J. 
Cardiovasc. Surg. 15: 356, 1974. 
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